Abstract
liver enzyme elevation was observed in 4 patients (16%) two months after the completion of the treatment. No classic RILD was observed. Conclusions: SBRT is a safe and effective therapeutic option for HCC lesions unsuitable to standard locoregional therapies, with acceptable rates of local control and low treatment-related toxicity. Author Disclosure: M. Scorsetti: None. T. Comito: None. M. Campisi: None. E. Clerici: None. L. Cozzi: K. Advisory Board; Scientific advisor to Varian Medical Systems. A. Tozzi: None. P. Navarria: None. C. Iftode: None. E. Villa: None. P. Mancosu: None. F. Lobefalo: None. S. Tomatis: None.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
